Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
Monday, June 03, 2024
Breakout Session
![Business Development and Finance](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Busines_MTC.png)
32AB
The 34th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth quantitative and qualitative look at the US and European biotechnology industry’s standing within a complex financing, regulatory and fast evolving healthcare environment. Despite a near closure of the IPO window and a difficult venture capital raising landscape following the sugar high during the pandemic, the start-up innovation engine of the pharmaceutical ecosystem continues to produce novel treatments. Biotech’s are advancing novel molecular entities – many enabled by new technologies such as cell and gene therapies, mRNA, Antibody-Drug Conjugates (ADC), CAR-T, while using generative AI/ML to create efficiencies in the process. We will explore these current topics – and more – during the Beyond Borders session.
Moderator
Speakers
![](https://www.conferenceharvester.com/uploads/harvester/photos/XDQDGWMO-Presenter-RyanB.jpg)
Board Member, Senior Advisor to EY, Indivior, Mink, Invo, SafeCor Pharmaceutical Companies
![](https://www.conferenceharvester.com/uploads/harvester/photos/XDQDGWMO-Presenter-BronkB.jpg)
Head of Business Development, Neurology, Rare Diseases, Technology Platforms and R&D Transactions Partnering
Sanofi